The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects - Wikidata - wikimedia - TriplyDB

The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects

The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects

http://www.wikidata.org/entity/Q35166849

about

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes.Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes.

P2860

Q35910737-1982ECC5-A155-4B0C-953E-A87FBFD5DD32 Q42371748-0ACF5778-5710-454F-A3F1-3E3CE77463CA

P2860

The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects

http://www.wikidata.org/entity/Q35166849

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects

@ast

The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects

@en

type

label

The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects

@ast

The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects

@en

prefLabel

The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects

@ast

The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects

@en

P1433

Q35166849-5CFF490A-8CAF-4785-B72E-D2448504F819

P1476

Q35166849-5AAF7EE1-AE50-4446-A40C-765482955D1A

P2093

Q35166849-11212924-DB61-40BE-BD1C-129BDA1559E2

Q35166849-134DDCB2-AD08-4CB9-B1E0-68886AD0A814

Q35166849-3FA6A628-9268-47A5-958C-1E4D6CD1D4FA

Q35166849-55F78F6F-01F0-4CF6-B714-7DB547D0E911

Q35166849-5A1BB84C-7F1F-47A7-9433-3EADDB1FAD1D

Q35166849-7DD67E7C-C4E8-41DC-BFDB-EBAC4643654A

Q35166849-9E9A05A0-1E6C-458B-974D-E1DFAA717DD6

Q35166849-A6A1F91D-1D5E-4248-95A0-6B880E344E16

Q35166849-BA3005EC-AC86-4D48-8EBC-70327857F5BE

Q35166849-D5C45742-9849-4272-B7CF-313E6A6E8FE7

P2860

Q35166849-1182E86E-7EED-4687-A697-79C85A1D5861

Q35166849-1A5596DA-ED63-4169-BA5E-50C772259EC3

Q35166849-448EEF69-98E0-4BB7-8BF9-859F0F3F7EC2

Q35166849-466E058B-C4D2-457F-B14F-04BBC2F9BFCB

Q35166849-48F90679-4BAB-44C3-8628-66D938C2987E

Q35166849-555FE7E6-39B9-4CC9-BBD3-198F7D1C47E1

Q35166849-5B456A0A-3297-4E2A-BEE9-C5E67BDD1159

Q35166849-608901AB-3BF3-4D7D-9A86-929E3D76D276

Q35166849-68716314-6E18-448C-8928-27CBFC914E79

Q35166849-74D359D0-DD7E-4C8E-A926-E432B905C5C0

P304

Q35166849-B5EC46C5-F10E-41DF-924A-D069A6CCFE06

P31

Q35166849-3CD1F59C-5E61-49A6-849A-2C8EFDB1D878

P356

Q35166849-AA4DA39C-7968-467A-8AF7-4C9CFA5F3342

P433

Q35166849-EA93F754-DD2E-45DB-8EFB-A1A01C8D360A

P478

Q35166849-081D5410-6CA3-4BE5-8881-A9933B90C546

P577

Q35166849-3785419C-79D5-407E-902B-8033F78F86BC

P5875

Q35166849-6CFC4DC0-9D83-4872-BA8E-18DA3231AD6D

P698

Q35166849-E511C1E2-71B9-4B95-8684-6992A565CB0B

P932

Q35166849-38B3EB7F-89A7-4F8C-A408-7113CEE70F9D

P356

P1433

Journal of clinical medicine research

P1476

The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects

@en

P2093

Daisuke Ito

http://www.w3.org/2001/XMLSchema#string

Hitoshi Ishida

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Inoue

http://www.w3.org/2001/XMLSchema#string

Kimie Kaneko

http://www.w3.org/2001/XMLSchema#string

Kouichi Inukai

http://www.w3.org/2001/XMLSchema#string

Morifumi Yanagisawa

http://www.w3.org/2001/XMLSchema#string

Shigehiro Katayama

http://www.w3.org/2001/XMLSchema#string

Takashi Sumita

http://www.w3.org/2001/XMLSchema#string

Takuya Awata

http://www.w3.org/2001/XMLSchema#string

Yuichi Ikegami

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients.

Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes

Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus.

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.

Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis.

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.

Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.

P304

303-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/JOCMR2057W

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273700552

http://www.w3.org/2001/XMLSchema#string

P698

25780477

http://www.w3.org/2001/XMLSchema#string

P932

4356089

http://www.w3.org/2001/XMLSchema#string